Precision Medicine

High quality mRNA for therapeutic application. Founded in 2022 and based in San Diego, California, Cisterna Biologics is a technology company. It aims to solve some of the challenges currently facing the biotech industry to develop mRNA-based therapeutics – quality, quantity, longevity and cost of mRNA. As mRNA technology matures, it becomes imperative that these issues are solved so we can fully explore mRNA's endless possibilities as a therapeutic. Cisterna uses proprietary technologies to either remove a contaminant at its source or replace the source itself. For example, to remove double-stranded RNA (dsRNA), we use ribozymes - molecular scissors - to precisely cut the mRNA at its 3’ end. This assures not only 3’ homogeneity, but also eliminates dsRNA, which are primarily produced due to self-templated additions at the 3’ end. Utilizing a PCR-like system to amplify the DNA template i

Unleashing the potential of DNA and RNA based therapies using AI. We have developed an AI platform enabling to accelerate the discovery and the design of genomic therapies such as Cell Therapies, RNA Therapies and DNA Therapies.

Software to launch and integrate genetics into clinical care. Nest is a lab-agnostic, comprehensive solution for organizations to launch and implement large-scale genomic programs. The platform includes the ability to triage, consent, and counsel patients for genetic testing, provide EMR-integrated clinical decision support for providers managing patients with genetic results, and manage patients’ clinical needs across the continuum of care.

Potent, durable, and redosable non-viral genetic medicines. Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine. In 2026 Engage was acquired by Eli Lilly.

Diversifying precision cancer diagnostics and treatments. Yemaachi Biotech is diversifying and expanding access to precision cancer diagnostics and therapeutics by collecting and sequencing samples from all across Africa, which is the most genetically diverse population on the planet. We then use this data to either optimize existing diagnostic tests, or help other companies discover new ones. With our research activities based in Africa, we are able to leverage access to the most genetically diverse population on the planet to build a first-of-its-kind clinical and molecular knowledgebase on cancer among African people.

Unlocking the next generation of mRNA medicines. The future of mRNA therapeutics is hampered by manufacturing challenges and unless solved, its exciting potential may never be realised. Sensible enables the next generation of mRNA medicines by turning living cells into factories producing abundant, highly stable and non-immunogenic mRNA in a scalable and cost-effective way.

Pioneering Breast Cancer Diagnostics for a Healthier Tomorrow. In the global fight against breast cancer, Digistain stands at the forefront, offering a beacon of hope to millions. Our journey began at Imperial College London, where ground-breaking research gave birth to a technology poised to revolutionize breast cancer diagnostics. The Challenge: Every year, breast cancer affects 2.3 million individuals globally. Post-surgery, 60% of patients are advised to undergo genomic testing, an expensive and time-consuming process monopolized by a single lab in the U.S., costing around $4,000 and taking nearly two months. Consequently, only 5% undergo this vital testing. The rest, unable to access this crucial diagnostic step, often resort to chemotherapy—a treatment that, in one in four cases, is more harmful than the cancer itself. Our Solution: Digistain addresses this critical gap. Our techno

Genetic Medicine with Small Molecules. Serna Bio is developing small molecules to modulate RNA function, unlocking the potential to treat diseases driven by biology intractable by other modalities.

PipeBio is a SaaS bioinformatics platform to develop antibody drugs.. Pipe|bio is the bioinformatics cloud for antibody / peptide screening & drug development. We enable scientists to analyze and manage massive amounts of DNA sequencing data themselves without the need for bioinformaticians or programmers. The software is highly visual and enables you to overlay and filter information from different sources across your organization; be it assay data, sequence data or other process metadata. Insights from past results can be used to guide new experiments and they get better as you upload more and more data. Team leads get oversight and these capabilities combined empower organizations to find better drugs, faster. We believe that science moves faster when scientists can curate and analyse their own data.

Desktop DNA Printer. The Nespresso Machine for DNA.. We combined microfluidic chip technology and a reagent cartridge to create the first personal DNA synthesizer. Until now most life scientists had to rely on out-sourced DNA synthesis, causing stagnating research. Kilobaser empowers every life scientist to synthesize DNA on their benchtop.